Our study suggests that the inhibition of cMet, FGFR, or non-EGFR receptor tyrosine kinases (RTK) may potentiate the inhibitory effect of erlotinib in NSCLC with a higher EGFR expression, especially for acquired erlotinib-resistant lung cancer. This evidence concerns the gene MET and lung carcinoma.